283 related articles for article (PubMed ID: 18793655)
1. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
[TBL] [Abstract][Full Text] [Related]
2. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
Radek RJ; Robb HM; Stevens KE; Gopalakrishnan M; Bitner RS
J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
[TBL] [Abstract][Full Text] [Related]
3. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.
Feuerbach D; Nozulak J; Lingenhoehl K; McAllister K; Hoyer D
Neurosci Lett; 2007 Apr; 416(1):61-5. PubMed ID: 17314009
[TBL] [Abstract][Full Text] [Related]
4. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice.
Schreiber R; Dalmus M; De Vry J
Psychopharmacology (Berl); 2002 Jan; 159(3):248-57. PubMed ID: 11862357
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
6. Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors.
Arias HR; De Rosa MJ; Bergé I; Feuerbach D; Bouzat C
Biochemistry; 2013 Nov; 52(47):8480-8. PubMed ID: 24164482
[TBL] [Abstract][Full Text] [Related]
7. Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
Pieschl RL; Miller R; Jones KM; Post-Munson DJ; Chen P; Newberry K; Benitex Y; Molski T; Morgan D; McDonald IM; Macor JE; Olson RE; Asaka Y; Digavalli S; Easton A; Herrington J; Westphal RS; Lodge NJ; Zaczek R; Bristow LJ; Li YW
Eur J Pharmacol; 2017 Jul; 807():1-11. PubMed ID: 28438647
[TBL] [Abstract][Full Text] [Related]
8. (R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
Tatsumi R; Fujio M; Takanashi S; Numata A; Katayama J; Satoh H; Shiigi Y; Maeda J; Kuriyama M; Horikawa T; Murozono T; Hashimoto K; Tanaka H
J Med Chem; 2006 Jul; 49(14):4374-83. PubMed ID: 16821797
[TBL] [Abstract][Full Text] [Related]
9. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism.
Simosky JK; Stevens KE; Adler LE; Freedman R
Psychopharmacology (Berl); 2003 Feb; 165(4):386-96. PubMed ID: 12459928
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
Martin LF; Freedman R
Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
[TBL] [Abstract][Full Text] [Related]
11. Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor.
Arias HR; Gu RX; Feuerbach D; Wei DQ
Biochemistry; 2010 May; 49(19):4169-80. PubMed ID: 20377277
[TBL] [Abstract][Full Text] [Related]
12. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
13. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Mastropaolo J; Rosse RB; Deutsch SI
Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
[TBL] [Abstract][Full Text] [Related]
14. Effects of nicotine vary across two auditory evoked potentials in the mouse.
Metzger KL; Maxwell CR; Liang Y; Siegel SJ
Biol Psychiatry; 2007 Jan; 61(1):23-30. PubMed ID: 16497274
[TBL] [Abstract][Full Text] [Related]
15. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
[TBL] [Abstract][Full Text] [Related]
16. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
Prickaerts J; van Goethem NP; Chesworth R; Shapiro G; Boess FG; Methfessel C; Reneerkens OA; Flood DG; Hilt D; Gawryl M; Bertrand S; Bertrand D; König G
Neuropharmacology; 2012 Feb; 62(2):1099-110. PubMed ID: 22085888
[TBL] [Abstract][Full Text] [Related]
17. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
[TBL] [Abstract][Full Text] [Related]
18. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.
Sydserff S; Sutton EJ; Song D; Quirk MC; Maciag C; Li C; Jonak G; Gurley D; Gordon JC; Christian EP; Doherty JJ; Hudzik T; Johnson E; Mrzljak L; Piser T; Smagin GN; Wang Y; Widzowski D; Smith JS
Biochem Pharmacol; 2009 Oct; 78(7):880-8. PubMed ID: 19615981
[TBL] [Abstract][Full Text] [Related]
19. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
[TBL] [Abstract][Full Text] [Related]
20. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
